Multi-Year Registry Study of Elapegademase Treatment in Patients With Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID) Requiring Enzyme Replacement Therapy
Journal of Clinical Immunology · 2025
DOI: 10.1007/s10875-025-01873-3 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Clinical Immunology, 2025. Verfasst von Morna J Dorsey und 19 weiteren Autor:innen. Beteiligte Einrichtung: University of California San Francisco Medical School, San Francisco, CA, USA. Morna.Dorsey@ucsf.edu. Hauptthemen laut MEDLINE: Adenosine Deaminase, Agammaglobulinemia, Enzyme Replacement Therapy, Severe Combined Immunodeficiency. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Leadiant Biosciences, Inc, Chiesi USA, Inc, DBV Technologies.
Abstract (Originalsprache)
Purpose
The safety and tolerability of elapegademase (elapegademase-lvlr; Revcovi ® ) a PEGylated recombinant adenosine deaminase (ADA), were demonstrated in two Phase 3 clinical trials in the U.S. and Japan in patients with ADA-deficient severe combined immunodeficiency (ADA-SCID). Elapegademase replaced Adagen ® (pegademase, a PEGylated bovine ADA) in 2018. This registry study (NCT03878069) was conducted as a post-marketing requirement to bolster the limited safety and effectiveness data on elapegademase in patients with ADA-SCID and to study patients starting on enzyme replacement therapy (ERT) de novo .
Methods
Patients were managed by routine clinical care and treating physicians’ judgement from September 2019 to January 2023. Primary endpoints included trough plasma ADA activity and total trough erythrocyte deoxyadenosine nucleotides (dAXP). Secondary outcomes included lymphocyte counts, hospitalizations, infections, and safety outcomes.
Results
Thirty-two patients were grouped as ERT-naïve ( n = 7; infants and children with no prior ERT [EN]); pegademase-transitioning ( n = 21; from pegademase to elapegademase [PT]); and patients who had participated in the Phase 3 clinical trial ( n = 4; STP-2279-002; [STP]). The EN group maintained optimal plasma ADA activity, increased lymphocyte counts, had manageable infections, and had no mortality for up to 30 months while on elapegademase. The STP group and 66.7% of the PT group continued to maintain satisfactory levels of both ADA and dAXP with stable rates of infections and hospitalizations and stable lymphocyte counts for up to 48.6 months. Variability on all measures was seen, but overall, patients did not deteriorate while on elapegademase.
Conclusion
Effectiveness of elapegademase was maintained up to 4 years of use and with no new safety concerns.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of California San Francisco Medical School, San Francisco, CA, USA. Morna.Dorsey@ucsf.edu.
- University of California Los Angeles, Los Angeles, CA, USA.
- University of Tennessee Health Science Center, Memphis, TN, USA.
- University of Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA.
- Penn State Health Hershey Medical Center, Hershey, PA, USA.
- Children's National Hospital, Washington, DC, USA.
ORCID-Profile: Morna J Dorsey, Manish J Butte, Jay A Lieberman, Heather Lehman, Tracy Fausnight, Michael D Keller, Caroline Fradette, Michael S Hershfield, Tamara C Pozos, Anna Rozova, Luke A Wall, Jeffrey J Bednarski, Teresa K Tarrant, Hey J Chong, Bob Geng, Noemi Toiber Temin, Susan S Laubach, Leo Lin, Talal Mousallem, Jolan E Walter
Förderung
- Leadiant Biosciences, Inc
- Chiesi USA, Inc
- DBV Technologies
Zitieren
APA
Dorsey, M. J., Butte, M. J., Lieberman, J. A., Lehman, H., Fausnight, T., Keller, M. D., Fradette, C., Hershfield, M. S., Pozos, T. C., Rozova, A., Wall, L. A., Bednarski, J. J., Tarrant, T. K., Chong, H. J., Geng, B., Temin, N. T., Laubach, S. S., Lin, L., Mousallem, T., & Walter, J. E. (2025). Multi-Year Registry Study of Elapegademase Treatment in Patients With Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID) Requiring Enzyme Replacement Therapy. Journal of Clinical Immunology. https://doi.org/10.1007/s10875-025-01873-3
Vancouver
Dorsey MJ, Butte MJ, Lieberman JA, Lehman H, Fausnight T, Keller MD, et al. Multi-Year Registry Study of Elapegademase Treatment in Patients With Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID) Requiring Enzyme Replacement Therapy. Journal of Clinical Immunology. 2025. doi:10.1007/s10875-025-01873-3
BibTeX
@article{Dorsey2025,
author = {Dorsey, Morna J and Butte, Manish J and Lieberman, Jay A and Lehman, Heather and Fausnight, Tracy and Keller, Michael D and Fradette, Caroline and Hershfield, Michael S and Pozos, Tamara C and Rozova, Anna and Wall, Luke A and Bednarski, Jeffrey J and Tarrant, Teresa K and Chong, Hey J and Geng, Bob and Temin, Noemi Toiber and Laubach, Susan S and Lin, Leo and Mousallem, Talal and Walter, Jolan E},
title = {Multi-Year Registry Study of Elapegademase Treatment in Patients With Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID) Requiring Enzyme Replacement Therapy},
journal = {Journal of Clinical Immunology},
year = {2025},
doi = {10.1007/s10875-025-01873-3}
}
EUVIMED